Nucleoside analog-associated sensory neuropathy (NRTI-SN) attributed to stavudine, didanosine, or zalcitabine (the dNRTIs) and distal sensory polyneuropathy (DSP) attributed to HIV are clinically indistinguishable. As inflammatory cytokines are involved in DSP, we addressed a role for inflammation in NRTI-SN by determining the alleles of immune-related genes carried by patients with and without NRTI-SN. Demographic details associated with risk of various neuropathies were included in the analysis. Alleles of 14 polymorphisms in 10 genes were determined in Australian HIV patients with definite NRTI-SN (symptom onset Ͻ6 months after first dNRTI exposure, n ‫؍‬ 16), NRTI-SN-resistant patients (no neuropathy despite Ͼ6 months on dNRTIs, n ‫؍‬ 20), patients with late onset NRTI-SN (neuropathy onset after Ͼ6 months of dNRTIs, n ‫؍‬ 19), and HIV-negative controls. Carriage of TNFA-1031*2 was highest in NRTI-SN patients, suggesting potentiation of NRTI-SN. Carriage of IL12B (3Ј UTR)*2 was higher in NRTI-SN-resistant patients than controls or NRTI-SN patients, suggesting a protective role. BAT1 (intron 10)*2 was more common in NRTI-SN than resistant patients, but neither group differed from controls. This marks the conserved HLA-A1, B8, DR3 haplotype. Of the demographic details considered, increasing height was associated with NRTI-SN risk. A model including cytokine genotype and height predicted NRTI-SN status (p Ͻ 0.0001, R 2 ‫؍‬ 0.54). Late onset NRTI-SN patients clustered genetically with NRTI-SN-resistant patients, so these patients may be genetically "protected." In addition to patient height, cytokine genotype influenced NRTI-SN risk following dNRTI exposure, suggesting inflammation contributes to NRTI-SN. 117 
INTRODUCTION
A NTIRETROVIRAL THERAPY (ART) has dramatically improved life expectancy with HIV infection, 1 but toxic effects from ART are evident in a subset of patients. Nucleoside analog-associated sensory neuropathy (NRTI-SN) is a common, disabling, and typically irreversible toxicity of ART. 2 High rates of neuropathy are now reported from HIV treatment centers throughout the world. The debilitating nature of NRTI-SN, its high prevalence, and the limited efficacy of current treatments 2 make this a clinically important problem.
NRTI-SN is clinically and histologically similar to distal sensory polyneuropathy (DSP) caused by HIV itself. The only distinguishing feature is the temporal relationship between symptom onset and exposure to particular nucleoside analog reverse transcriptase inhibitors (NRTIs): zalcitabine (ddC), stavudine (d4T), or didanosine (ddI) (denoted dNRTI) in NRTI-SN. 2 Thus, dNRTI exposure is both a diagnostic marker and a primary risk factor for NRTI-SN. Although ddC is no longer in clinical use, d4T continues to be included in first line ART in many countries to avoid the higher cost and risk of anemia with AZT.
NRTI-SN does not affect all patients treated with a dNRTI, and most cases occur in the first 6 months of exposure. 2 The demographic and treatment predispositions described only partly predict the individual's NRTI-SN risk. [2] [3] [4] The following lines of evidence suggest that genetic markers of host inflammatory responses may further refine a prediction of risk for NRTI-SN: Here we addressed known polymorphisms in immune-related genes as determinants of NRTI-SN risk following dNRTI exposure. Several genes studied lie in the MHC. These include HSPA1B, 13 TNFA, and BAT1. A polymorphism in intron 10 of BAT1 provides a specific marker of the central MHC region characteristic of the 8.1 haplotype (HLA-A1, B8, DR3), which is associated with multiple immunopathological diseases. 14, 15 Demographic details, including patient height, 16 have previously been associated with risk of various neuropathies. These were included to obtain an optimal model for the prediction of NRTI-SN risk with dNRTI exposure.
MATERIALS AND METHODS
Patients were selected from the Australian arm of a cohort study examining the effects of HIV and its treatment on the peripheral nervous system. 3 Individuals with any established risk factor for neuropathy other than HIV infection or antiretroviral exposure (including diabetes mellitus or a history of excessive alcohol consumption) were excluded from the parent study. All subjects were adults (Ն18 years) with HIV infection attending the Alfred Hospital Infectious Diseases Clinic in Melbourne, Australia. All but two were white. Detailed demographic, treatment, and clinical details were available on all subjects. Controls were retired donors from the West Australian Bone Marrow Registry (Ͼ95% white and presumed to be HIV negative, n ϭ 79-270). This work was approved by the local Human Research and Ethics Committee, and was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2000. All patients gave written, informed consent to participate. 
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Assessment of neuropathy
Patients were assessed for peripheral neuropathy using the AIDS Clinical Trials Group Brief Peripheral Neuropathy Screen (ACTG BPNS). 17 Neuropathy was defined as present if the individual had at least one of the lower limb neuropathic symptoms elicited using this tool (pain, aching or burning, pins and needles, or numbness) together with at least one of absent ankle reflexes or reduced vibration sense at the great toe (vibration of a 128-Hz tuning fork felt for 10 s or less). Patients were defined as neuropathy free if they had no lower limb neuropathic symptoms and had normal ankle reflexes and normal vibration sense at the great toe bilaterally. All patients from the cohort who met one of the following criteria were included:
1. Definite NRTI-SN: Patients with neuropathy (symptoms and signs on the ACTG BPNS) in whom symptom onset occurred within the first 6 months of exposure to their first dNRTI.
NRTI-SN resistant:
Patients who remain neuropathy free (no symptoms and no signs on the ACTG BPNS) despite at least 6 months of cumulative exposure to at least one dNRTI.
Late onset NRTI-SN:
Patients with neuropathy (symptoms and signs on the ACTG BPNS) where symptom onset occurred after Ͼ6 months of dNRTI exposure.
DNA extraction and genotyping
Patient peripheral blood mononuclear cells were obtained by Ficoll density gradient centrifugation and DNA was extracted using the QIAamp DNA Mini Kit (Qiagen Inc., Chatsworth, CA) according to the manufacturer's protocols.
Genomic DNA was screened using established PCR restriction fragment length polymorphism (RFLP) assays to determine the alleles carried at IL1Bϩ3953 and BAT1 (intron 10) (rs9281523), IL6-174, 5,18 IL12B (3Ј UTR), 19 TNFA-308 (rs1800629), 20 HSPA1Bϩ1267, 13 IL4-589, TNFA-1031 (rs1799964), and IL10-592. 21 IL10-1082 and IL10R1ϩ1112 alleles were determined by PCR-confronting two pair primers. 22, 23 Other assays were based on FAM and VIC-labeled probes and Universal PCR Master Mix (Taqman, Applied Biosystems) in 5 l reactions. Assay IDs were C_9546471_10 for IL1Aϩ4845 (rs17561), C_2408543_10 for IL18-137 (rs187238), and C_2890460_10 for IL18-607 (rs1956518). Control samples carrying (1,1), (1,2), and (2,2) were included in all runs.
Data analysis
Statistical analyses were performed using Stata 9.2 (StataCorp, USA). To accommodate small numbers with the (2,2) genotype at most loci, genotypes were grouped as (1,1) versus (1,2 or 2,2) in all analyses. Associations between alleles and NRTI-SN status (and with controls) were assessed individually using 2 tests. Demographic details of patients with and without NRTI-SN were compared using 2 or unpaired t tests, as appropriate. Multivariate analyses were undertaken using multiple case-control logistic regression with a reverse selection procedure.
RESULTS
Associations between genotype and a definite diagnosis of NRTI-SN
Univariate analyses of genotype and NRTI-SN status (resistant versus definite; Table 1A ) showed increased carriage of TNFA-1031*2 (p ϭ 0.01) and reduced carriage of IL12B (3Ј UTR)*2 (p ϭ 0.03) in patients with definite NRTI-SN. Weak associations were noted with BAT1 (intron 10)*2 and TNFA-308*2, where these alleles were in linkage disequilibrium. The multivariate analysis included all alleles where p Ͻ 0.3, but BAT1 (intron 10) was used (rather than TNFA-308) because it is a specific marker of TNF gene block of the HLA-A1, B8, DR3 haplotype. Some individuals with TNFA-308*2 carry other haplotypes. 15 A model including BAT1 (intron 10), TNFA-1031, and IL12B (3Ј UTR) was highly significant overall (p ϭ 0.001; Table 1B) .
Comparison with HIV-negative control populations
Frequencies of alleles associated with NRTI-SN in the multivariate analysis were compared with data from populationbased control populations of similar ethnicity (Table 2) . Carriage of TNFA-1031*2 was higher in patients with NRTI-SN (compared with controls and NRTI-SN-resistant patients), so we associate this allele with susceptibility to NRTI-SN. In contrast, IL12B (3Ј UTR)*2 is overrepresented among NRTI-SNresistant patients (compared with controls and patients with NRTI-SN), so we associate this allele with resistance to NRTI-SN. Although BAT1 (intron 10)*2 tended to occur more often in NRTI-SN patients (compared with controls and NRTI-SNresistant patients), the differences were not significant. 
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Inclusion of patients with late onset NRTI-SN in the model
Patients defined as having late onset NRTI-SN (n ϭ 19) had neuropathy, but their symptoms began after Ͼ6 months of exposure to a dNRTI (mean time on a dNRTI prior to NRTI-SN symptom onset was 29 months, range 7-54 months). These subjects were similar to those with NRTI-SN in terms of age when tested, age at first exposure to a dNRTI, and nadir CD4 T cell count (t test, p Ͼ 0.05; data not shown). We addressed whether they are genetically predisposed to NRTI-SN or are moderately protected from this complication of dNRTI therapy (Table 3A) . When late onset NRTI-SN patients were grouped with patients with definite NRTI-SN in the logistic regression analysis, the optimal model CHERRY ET AL. 120 was not significant (p ϭ 0.12) and no SNP examined was independently associated with NRTI-SN status (p Ͼ 0.05). Hence patients with late onset NRTI-SN are genetically distinct from those with definite NRTI-SN. However, when late onset NRTI-SN patients were grouped with NRTI-SN-resistant patients, the model was highly significant (p ϭ 0.001; Table 3B )
Inclusion of demographic details in the model
Clinical details including age, 2,3 plasma lactate 24 exposure to protease inhibitors, 25, 26 and perhaps hepatitis C status 27 have previously been associated with NRTI-SN risk. Demographic details of study patients (n ϭ 55, Table 4A ) identify patient height as the only feature associated with NRTI-SN status (p ϭ 0.0001). Our logistic regression model for predicting NRTI-SN risk was enhanced by adjusting for patient height (p Ͻ 0.0001, R 2 ϭ 0.54; Table 4B ).
DISCUSSION
These data suggest a role for cytokine genotype in predicting an individual's risk of NRTI-SN following dNRTI exposure. In this predominantly white population of Australian adults with HIV infection, carriage of TNFA-1031*2 was more common in patients with definite NRTI-SN (relative to control donors), suggesting this allele marks susceptibility to NRTI-SN. In contrast, carriage of IL12B (3Ј UTR)*2 was common in NRTI-SN-free patients (compared with controls), suggesting carriers of this allele are relatively protected from NRTI-SN.
TNFA-1031*2 was the allele most strongly associated with NRTI-SN status and was overrepresented among patients with definite NRTI-SN compared with control populations. It is not currently clear whether carriage of this allele affects TNF-␣ production. However, TNF-␣ is known to play a role in HIVassociated neurological disease, including peripheral neuropathy. 7, 8 TNFA-1031*2 occurs in a TNFA haplotype associated with Behcet's disease, 28 a condition associated with local increases in TNF-␣. 29 Further, alleles at several loci upstream of TNFA (including TNFA-1031) associate with poor control of HIV viremia 30 and with HIV-associated lipodystrophy. 31 Therefore, the association between TNFA-1031*2 and NRTI-SN following dNRTI exposure is biologically plausible and consistent with findings from other disease states.
TNFA-308*2 and BAT1(intron 10)*2 were weakly associated with NRTI-SN status in this cohort (p ϭ 0.1), but emerged as significant in the multivariate analysis. In whites, these alleles mark carriage of the 8.1 haplotype (HLA-A1, B8, DR3), which has been linked with multiple immunopathological conditions, including rapid progression to AIDS. 32 BAT1 (intron 10)*2 is a more specific marker of the 8.1 haplotype than TNFA-308*2. 14 TNFA-308*2 has been associated with increased TNF-␣ production, but this finding is controversial. 33 The allele also associates with an increased risk of HIV dementia 6 and a poorer outcome in infectious diseases including cerebral malaria in Africans. 34 However, the TNF block haplotype containing TNFA-308*2 in Africans is highly conserved and matches that of the white 8.1 haplotype, 35 so it is not valid to associate these phenotypes with any single allele.
The clear effect of TNFA-1031*2 on NRTI-SN suggests TNF block haplotypes containing this allele also affect NRTI-SN. Using 19 polymorphisms, we defined 17 haplotypes in this region that account for around 90% of control donors in the Western Australian population. 15 We plan to examine haplotypic associations with NRTI-SN using these protocols, as a polymorphism shared by haplotypes associated with NRTI-SN in different ethnic populations is more likely to contribute to pathogenesis. TNFA-1031*2 is found in five conserved MHC haplotypes (unpublished observations).
Our data also suggest a role for the IL12B genotype in NRTI-SN. IL12B(3Ј UTR)*2 was more common in patients who were NRTI-SN resistant compared with controls or those with NRTI-SN, suggesting a protective role for this allele. We have also found IL12B (3Ј UTR)*2 is rare in HIV patients who experience immune reconstitution disease associated with previous herpes virus infections following ART. 5 In healthy donors, carriage of allele 2 associates with elevated IL-12p70 synthesis by blood monocytes stimulated in vitro. 36 Hence, a role for IL-12B alleles in NRTI-SN warrants investigation in a larger cohort.
We examined polymorphisms in other genes previously associated with the immunopathology of HIV-related and other infectious diseases, including IL1A, 18 39 and HSPA1B. 13 We found no associations between alleles of these genes and NRTI-SN. Future studies will include other ethnicities.
Patients who developed neuropathy after more than 6 months on a dNRTI had genotypes similar to those who were NRTI-SN resistant. There is no objective method of differentiating NRTI-SN from neuropathy due to HIV itself, 2 with the diagnosis of NRTI-SN resting on the temporal relationship of symptom onset to dNRTI exposure. NRTI-SN was the dose-limiting toxicity in early clinical trials of all dNRTIs, and was found to be universal given sufficient doses of ddC. 2 Hence patients who are not genetically predisposed to NRTI-SN may develop neuropathy following sufficient dNRTI exposure.
Peripheral sensory nerves are supported by active transport of essential compounds down long processes from the dorsal root ganglia. This highly energy-dependent process would be vulnerable to mitochondrial toxins such as dNRTIs. This may be most apparent in taller patients, as they have an increased risk of various peripheral neuropathies. 16, 40 Height was associated with NRTI-SN in this cohort. A model including cytokine genotype and height was strongly associated with NRTI-SN status, supporting our hypothesis that the host inflammatory response is also important in NRTI-SN pathogenesis.
In conclusion, we have developed a model to predict NRTI-SN based on a patient's height and cytokine genotype in an Australian cohort. Following confirmation in larger cohorts from ethnically distinct populations, this has the potential to facilitate more rational selection of ART regimens.
